Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study Comparing Mindfulness Apps to Decrease Anxiety in People With Lung Cancer

Not Applicable

Active, not recruiting

Conditions: Lung Cancer

Interventions: Other: AmDTx-PCSP
Other: AmDTx-2048
Other: Questionnaires

First Posted Date: 2023-08-23

Last Posted Date: 2024-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT06008574

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of Contrast-Enhanced Mammography (CEM) Scans in People With Breast Cancer

Withdrawn

Conditions: Breast Cancer

Interventions: Diagnostic Test: Contrast-Enhanced Mammography
Diagnostic Test: Breast MRI

First Posted Date: 2023-08-14

Last Posted Date: 2025-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT05990478

A Study of Stereotactic Radiosurgery (SRS) to Treat Pain in the Chest and/or Stomach Wall

Phase 1

Recruiting

Conditions: Thoracoabdominal Wall Pain
Secondary to Parietal Pleura or Parietal Peritoneum Disease

Interventions: Radiation: Single-fraction stereotactic radiosurgery (SRS)

First Posted Date: 2023-08-14

Last Posted Date: 2025-01-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT05985148

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

and more 4 locations

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Phase 2

Recruiting

Conditions: Wilms Tumor
Malignant Peripheral Nerve Sheath Tumors
Rhabdoid Tumor
XPO1 Gene Mutation
Solid Tumor
MPNST
Nephroblastoma

Interventions: Drug: Selinexor

First Posted Date: 2023-08-14

Last Posted Date: 2025-05-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT05985161

Locations: 🇺🇸
Children's Hospital of Los Angeles (Data Collection Only), Los Angeles, California, United States
🇺🇸
Standford Medicine Children's Health, Palo Alto, California, United States
🇺🇸
Children's National Hospital, Washington, District of Columbia, United States

and more 12 locations

A Registry for People With T-cell Lymphoma

Recruiting

Conditions: Chronic Lymphoproliferative Disorder of NK Cells
Aggressive NK-cell Leukemia
Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)
Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood
Extranodal NK/T-cell Lymphoma, Nasal Type
Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
Mycosis Fungoides
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
T-cell Lymphoma
Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form

Interventions: Other: Optional Blood Sample and Nail Sample

First Posted Date: 2023-08-07

Last Posted Date: 2025-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1000

Registration Number: NCT05978141

Locations: 🇺🇸
Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts, United States
🇺🇸
University of Miami (Data Collection Only), Miami, Florida, United States
🇺🇸
University of Nebraska (Data collection only), Omaha, Nebraska, United States

and more 23 locations

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Benralizumab
Drug: fulvestrant or AIs) and PI3K inhibition (alpelisib)

First Posted Date: 2023-07-28

Last Posted Date: 2024-08-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT05966584

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States

and more 4 locations

A Study of Changes in Heart Function and Blood Flow in People Receiving Anesthesia

Recruiting

Conditions: Anesthesia

Interventions: Diagnostic Test: Echocardiography

First Posted Date: 2023-07-20

Last Posted Date: 2024-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 250

Registration Number: NCT05954832

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York, United States

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Not Applicable

Recruiting

Conditions: Lymphoma
Large-cell Lymphoma
Large B-cell Lymphoma
Mediastinal B-Cell Diffuse Large Cell Lymphoma
Lymphoma, B-Cell
DLBCL - Diffuse Large B Cell Lymphoma

Interventions: Behavioral: Hematolo-GIST Training
Behavioral: Participants Appointment

First Posted Date: 2023-07-11

Last Posted Date: 2025-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 48

Registration Number: NCT05940272

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York, United States
🇺🇸
NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York, New York, United States

Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma

Not Applicable

Withdrawn

Conditions: Glioblastoma

Interventions: Diagnostic Test: Lumber Puncture

First Posted Date: 2023-07-03

Last Posted Date: 2025-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT05927610

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Drug: IO102/IO103
Drug: Nivolumab-Relatlimab

First Posted Date: 2023-06-22

Last Posted Date: 2025-05-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 43

Registration Number: NCT05912244

Locations: 🇺🇸
Hartford Healthcare Alliance (Data Collection Only), Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States

and more 6 locations

Home Terms & Conditions Privacy Policy